Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.71 |
| ▸ | PARP1 | P09874 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.59 |
| ▸ | BRD1 | O95696 | 1/20 | 0.59 |
| ▸ | BRD2 | P25440 | 1/20 | 0.59 |
| ▸ | IL17A | Q16552 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053829 | 1.00 | BRD4 (0.71) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| SCHEMBL348894 | 0.92 | BRD4 (0.77) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| SCHEMBL378378 | 0.91 | BRD4 (0.58) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| SCHEMBL146582 | 0.91 | BRD4 (0.60) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| SCHEMBL30434847 | 0.91 | BRD4 (0.60) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| SCHEMBL30052491 | 0.89 | BRD4 (0.70) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| SCHEMBL349178 | 0.89 | BRD4 (0.70) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| SCHEMBL121780 | 0.88 | HDAC1 (0.58) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| SCHEMBL30434491 | 0.88 | HDAC1 (0.58) | BRD4PARP1HDAC1HDAC3HDAC4 | |
| Apabetalone SCHEMBL145019 | 0.88 | BRD4 (0.84) | BRD4PARP1HDAC1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190091235-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2019-03-28 | — | — | US | claimed |
| US-10111885-B2 | Compositions and therapeutic methods for the treatment of complement-associated diseases | RESVERLOGIX CORP. (CA) | 2018-10-30 | — | — | US | claimed |
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | claimed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | claimed |
| EP-3268007-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | Resverlogix Corp. (CA) | 2018-01-17 | — | — | EP | claimed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | claimed |
| WO-2016147053-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | RESVERLOGIX CORP. (CA) | 2016-09-22 | — | — | WO | claimed |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2016-09-15 | — | — | US | claimed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | claimed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | claimed |
| US-20130108672-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUBSTITUTED QUINAZOLINONES | RESVERLOGIX CORP. (CA) | 2013-05-02 | — | — | US | claimed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | claimed |
| US-8114995-B2 | Methods of preparing quinazolinone derivatives | RESVERLOGIX CORP. (CA) | 2012-02-14 | — | — | US | claimed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | claimed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | claimed |
| JP-2011526287-A | — | — | 2011-10-06 | — | — | JP | claimed |
| EP-2346837-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2011-07-27 | — | — | EP | claimed |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2010-01-07 | — | — | US | claimed |
| WO-2009158404-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2009-12-30 | — | — | WO | claimed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885PARP1 3268/4885HDAC1 510/4885 |
| US-20130108672-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUBSTITUTED QUINAZOLINONES | APOB, APOL1, HDLBP | BRD4 1864/4885PARP1 3279/4885HDAC1 1436/4885 |
| US-10111885-B2 | Compositions and therapeutic methods for the treatment of complement-associated diseases | C5, CFH, C1QBP | BRD4 3811/4885PARP1 2459/4885HDAC1 2013/4885 |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 192/4885PARP1 901/4885HDAC1 639/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885PARP1 3268/4885HDAC1 510/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885PARP1 3268/4885HDAC1 510/4885 |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | C5, CFH, C1QBP | BRD4 3811/4885PARP1 2459/4885HDAC1 2013/4885 |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | APOB, APOL1, LDLR | BRD4 1306/4885PARP1 2049/4885HDAC1 1369/4885 |
| US-20190091235-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | C5, CFH, C1QBP | BRD4 3811/4885PARP1 2459/4885HDAC1 2013/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | BRD4 693/4885PARP1 3264/4885HDAC1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.